Overview
Single Dose Escalation Study of 131I-Sibrotuzumab in Patients With Advanced or Metastatic Non-small Cell Lung Cancer
Status:
Terminated
Terminated
Trial end date:
1969-12-31
1969-12-31
Target enrollment:
0
0
Participant gender:
All
All
Summary
Study to determine the maximum tolerated dose (MTD) and safety profile of a single-dose administration of sibrotuzumab (50 mg) conjugated to an increasing dose of 131 I isotope.Phase:
Phase 1Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Boehringer Ingelheim
Criteria
Inclusion Criteria:- Evidence of advanced, non-resectable, and/or metastatic non-small cell lung cancer and
at least one previous conventional treatment for advanced disease
- Eastern cooperative Oncology Group (ECOG) performance status of 0 or 1
- Measurable or evaluable disease, determined by World Health Organization (WHO)
criteria using standard imaging modalities, including ultrasound, X-ray, CT and/or
Magnetic Resonance Imaging (MRI). Bone scans and/or antibody scans are not to be used
to determine the extent of the disease
- Expected survival of ≥ 16 weeks
- At least 18 years of age
- Platelet count ≥ 100 x 10**9/L
- Absolute neutrophil count ≥ 2.0 x 10**9/L
- Aspartate aminotransferase (AST) ≤ 3 x upper limit of normal or < 5 x upper limit of
normal if liver metastases are present
- Total bilirubin ≤ 2mg/dL
- Serum creatinine ≤ 2mg/dL
- Ability to provide written informed consent
Exclusion Criteria:
- Known brain metastases
- Exposure to an investigational agent within 30 days prior to receiving the scout dose
- Incomplete recovery from surgery or incomplete healing of an incision site or evidence
of infection
- Treatment with cytotoxic chemotherapy, radiation or immunosuppressive therapy within
the 30 days (42 days for nitrosoureas and/or mitomycin C) of the scout infusion.
Patients using inhaled corticosteroids are considered eligible for enrollment
- Serious illnesses, i.e., active infections requiring antibiotics, bleeding disorders
or other serious illnesses precluding the use of either 131I or sibrotuzumab
- Women who are breast-feeding or pregnant
- Men and women who were sexually active and are unwilling to utilize a medically
acceptable method of contraception
- Hypertrophic skin disease or autoimmune disease that possibly involves over-expression
of fibroblast activation protein (FAP), which can be targeted by the antibody. These
diseases include active inflammatory arthritis, cirrhosis, and keloids
- Unstable angina pectoris. Patients prescribed medication to control their angina
pectoris must have been on a fixed dose for at least 1 month prior to screening to be
eligible for trial enrollment
- Myocardial infarction within 3 months prior to screening
- New York Heart Association (NYHA) Heart failure stage III or IV, or a left ventricular
ejection fraction of ≤ 40 %
- Impaired lung function, measured by a decrease in forced expiratory volume at one
second (FEV1) to less than 50 % of the predicted normal value